DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
Abbott Laboratories |
Kos Pharmaceuticals |
$3.7B buyout |
Kos makes Niaspan and Advicor, which boost "good" cholesterol, and is in late-stage development of Simcor. |
Merck |
Sirna Therapeutics |
$1.1B buyout |
Sirna's lead drug candidate, Sirna-027, is being developed as a treatment for wet, age-related macular degeneration. |
Allergan |
Groupe Corneal Laboratoires |
$216M buyout |
Allergan, which makes Botox, plans to separate the French companies' aesthetic and ophthalmic business with an eye to selling the ophthalmic division. |
Wyeth |
Ablynx |
$212M licensing deals |
Ablynx has agreed to license its Nanobodies technology to Wyeth. |
Lonza |
Genentech |
$150M purchase |
Switzerland's Lonza has struck a deal to buy a manufacturing plant in Spain from Genentech. |
Inspire Pharmaceuticals |
FAES Farma |
$89M licensing deal |
Inspire Pharmaceuticals gains U.S. and Canadian licensing rights to bilastine. |
Wyeth |
Inovio Biomedical |
$64.5M deal |
Wyeth will use Inovio Biomedical's DNA delivery technology for certain DNA vaccines in development. |
Roche |
InterMune |
$60M deal |
Roche has signed a deal to develop InterMune's experimental therapy for hepatitis C. |
Biomira |
ProlX Pharmaceuticals |
$23.9 buyout |
The acquisition will give Biomira control of Stimuvax, a synthetic MUC1 peptide vaccine now in Phase III, and PX-12, a thioredoxin inhibitor which is headed into Phase II. |
Cephalon |
Ambit |
$18 deal |
Cephalon is gaining access to Ambit's proprietary KinomeScan technology. |
Merck |
J. David Gladstone Institutes |
$3.25M collaboration and licensing pact |
The groups have signed a collaboration and licensing pact for the research and development of drugs to treat neurodegenerative diseases. |